药品详细

Cinoxacin(西诺沙星)

基本信息
剂型规格
适应症
药理
临床
理化性质
相互作用
文档
专利
Pathway
文献
序列

化学结构式图

中文名

西诺沙星

英文名

Cinoxacin

分子式

C₁₂H₁₀N₂O₅

化学名

1-ethyl-4-oxo-1H,4H,7H-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid

分子量

Average: 262.2182
Monoisotopic: 262.05897144

CAS号

28657-80-9

ATC分类

J01M 未知

药物类型

small molecule

阶段

approved

商品名

Cinobac;

同义名

基本介绍

Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. [PubChem]

生产厂家

Eli lilly and co
Teva pharmaceuticals usa inc

封装厂家

参考

Synthesis Reference	Not Available
General Reference	Not Available

剂型

规格

化合物类型

Type	small molecule

Classes

Cinnolines
Benzodioxoles

Substructures

Hydroxy Compounds
Acetates
Acetals and Derivatives
Phenols and Derivatives
Ethers
Benzene and Derivatives
Cinnolines
Pyridazines
Carboxylic Acids and Derivatives
Dioxoles
Catechols
Heterocyclic compounds
Aromatic compounds
Benzodioxoles
Anisoles
Imines
Phenyl Esters

适应症

antibacterials 抗细菌;

药理

Indication	For the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella species (including K. pneumoniae), and Enterobacter species.
Pharmacodynamics	Cinoxacin is a synthetic antibacterial agent with in vitro activity against many gram-negative aerobic bacteria, particularly strains of the Enterobacteriaceae family. Cinoxacin inhibits bacterial deoxyribonucleic acid (DNA) synthesis, is bactericidal, and is active over the entire urinary pH range. Cross resistance with nalidixic acid has been demonstrated.
Mechanism of action	Evidence exists that cinoxacin binds strongly, but reversibly, to DNA, interfering with synthesis of RNA and, consequently, with protein synthesis. It appears to also inhibit DNA gyrase. This enzyme is necessary for proper replicated DNA separation. By inhibiting this enzyme, DNA replication and cell division is inhibited.
Absorption	Rapidly absorbed after oral administration. The presence of food delays absorption but does does not affect total absorption.
Volume of distribution	Not Available
Protein binding	60 to 80%
Metabolism	Hepatic, with approximately 30-40% metabolized to inactive metabolites.
Route of elimination	Not Available
Half life	The mean serum half-life is 1.5 hours. Half-life in patients with impaired renal function may exceed 10 hours.
Clearance	Not Available
Toxicity	Oral, subcutaneous, and intravenous LD₅₀ in the rat is 3610 mg/kg, 1380 mg/kg, and 860 mg/kg, respectively. Oral, subcutaneous, and intravenous LD₅₀ in the mouse is 2330 mg/kg, 900 mg/kg, and 850 mg/kg, respectively.Symptoms following an overdose of cinoxacin may include anorexia, nausea, vomiting, epigastric distress, and diarrhea. The severity of the epigastric distress and the diarrhea are dose related. Headache, dizziness, insomnia, photophobia, tinnitus, and a tingling sensation have been reported in some patients.
Affected organisms	Enteric bacteria and other eubacteria
Pathways	Not Available

理化性质

Properties

State

solid

Experimental Properties

Property	Value	Source
melting point	261 dec °C	PhysProp
logP	1.5	Not Available

Predicted Properties

Property	Value	Source
water solubility	9.61e-01 g/l	ALOGPS
logP	1.25	ALOGPS
logP	1.72	ChemAxon
logS	-2.4	ALOGPS
pKa (strongest acidic)	4.93	ChemAxon
pKa (strongest basic)	-4.6	ChemAxon
physiological charge	-1	ChemAxon
hydrogen acceptor count	7	ChemAxon
hydrogen donor count	1	ChemAxon
polar surface area	88.43	ChemAxon
rotatable bond count	2	ChemAxon
refractivity	73.6	ChemAxon
polarizability	24.72	ChemAxon

药物相互作用

食物相互作用

Not Available

返回 | 收藏